GlobalData on MSN

Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

Hansa will apply to the EMA to convert Idefrix’s conditional approval into full marketing authorisation.

Cynata clears key European regulatory step toward future Phase 3 in acute graft versus host disease

Cynata Therapeutics has received a Positive Opinion from the European Medicines Agency’s Paediatric Committee (PDCO) on its ...
Clinical Pain Advisor

Autoimmune Disease Linked to Poor Outcomes With Myelodysplastic Syndrome

HealthDay News — Having a preexisting autoimmune disease is an independent risk factor for poor outcomes with myelodysplastic syndrome (MDS), according to a study published in the June issue of ...

Cynata Nears Key Data Readouts as Pivotal Cell Therapy Trials Advance

Detailed price information for Cynata Therapeutics Ltd (CYYNF) from The Globe and Mail including charting and trades.
Nature

Graft Versus Host Disease in Solid Organ Transplantation

Graft versus host disease (GVHD) following solid organ transplantation is a rare but often fatal complication arising when donor immune cells contained within the graft recognise recipient tissues as ...